VNDA Vanda Pharmaceuticals Inc.
Nasdaq · SEC CIK 1347178 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $2.82M 6 sales by 6 insiders
- Filings on record
- 110 since 2021-07-27, latest 2026-06-08 16:39
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | — | $1.28M |
| Moran Kevin Patrick | SVP, CFO, Treas | — | $351.0K |
| Williams Timothy | SVP, GC | — | $350.9K |
| Birznieks Gunther | SVP, Business Development | — | $350.9K |
| Wijkstrom Joakim | SVP, CMO | — | $254.7K |
| Honore Tage | Dir | — | $240.9K |
| McGuire Daniel Patrick | SVP, GC, Sec | — | — |
| Duncan Charles Cliff | Dir | — | — |
| Mitchell Stephen Ray | Dir | — | — |
| Ward Anne Sempowski | Dir | — | — |
Transactions 123
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-03 | 2022-06-02 | VNDA | Watkins Thomas | Dir | M - OptEx | $4.15 | +15.0K | 69.5K | +28% | +$62.3K |
| D | 2022-06-02 | 2022-05-31 | VNDA | DUGAN RICHARD W | Dir | M - OptEx | $4.15 | +15.0K | 74.9K | +25% | +$62.3K |
| D | 2022-06-02 | 2022-05-31 | VNDA | DUGAN RICHARD W | Dir | S - Sale+OE | $9.85 | -6,500 | 68.4K | -9% | -$64.0K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Wijkstrom Joakim | SVP, CMO | A - Grant | $0.00 | +32.7K | 107.3K | +44% | $0 |
| D | 2022-03-02 | 2022-03-02 | VNDA | Wijkstrom Joakim | SVP, CMO | S - Sale | $11.19 | -6,974 | 100.3K | -7% | -$78.0K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Williams Timothy | SVP, GC | A - Grant | $0.00 | +32.7K | 115.9K | +39% | $0 |
| D | 2022-03-02 | 2022-03-02 | VNDA | Williams Timothy | SVP, GC | S - Sale | $11.09 | -12.1K | 103.9K | -10% | -$133.7K |
| DM | 2022-03-02 | 2022-03-01+ | VNDA | Birznieks Gunther | SVP, Business Development | S - Sale | $11.25 | -15.6K | 188.8K | -8% | -$175.5K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Birznieks Gunther | SVP, Business Development | A - Grant | $0.00 | +32.7K | 204.4K | +19% | $0 |
| DM | 2022-03-02 | 2022-03-01+ | VNDA | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $11.25 | -12.3K | 119.7K | -9% | -$138.5K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Moran Kevin Patrick | SVP, CFO, Treas | A - Grant | $0.00 | +32.7K | 132.0K | +33% | $0 |
| D | 2022-03-02 | 2022-02-28 | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | A - Grant | $0.00 | +115.0K | 1.39M | +9% | $0 |
| DM | 2022-03-02 | 2022-03-01+ | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | S - Sale | $11.16 | -37.1K | 1.35M | -3% | -$413.9K |
| DM | 2021-12-02 | 2021-11-30+ | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir | M - OptEx | $4.88 | +150.0K | 1.32M | +13% | +$732.0K |
| DM | 2021-12-02 | 2021-11-30+ | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir | S - Sale+OE | $16.25 | -96.2K | 1.25M | -7% | -$1.56M |
| DM | 2021-09-17 | 2021-09-15 | VNDA | Jones Aranthan II | Chief Corp. Affairs Off | M - OptEx | $11.66 | +12.1K | 91.0K | +15% | +$141.3K |
| D | 2021-09-17 | 2021-09-15 | VNDA | Jones Aranthan II | Chief Corp. Affairs Off | S - Sale+OE | $16.49 | -16.8K | 82.0K | -17% | -$277.4K |
| D | 2021-09-13 | 2021-09-09 | VNDA | Mitchell Stephen Ray | Dir | S - Sale+OE | $16.74 | -19.1K | 9,215 | -67% | -$319.9K |
| DM | 2021-09-13 | 2021-09-09 | VNDA | Mitchell Stephen Ray | Dir | M - OptEx | $12.03 | +19.1K | 28.3K | +207% | +$229.9K |
| 2021-08-23 | 2021-08-20 | VNDA | Wijkstrom Joakim | SVP, CMO | S - Sale | $15.39 | -3,650 | 74.6K | -5% | -$56.2K | |
| 2021-08-17 | 2021-08-16 | VNDA | Williams Timothy | SVP, GC | S - Sale | $16.15 | -3,715 | 83.2K | -4% | -$60.0K | |
| 2021-07-30 | 2021-07-28 | VNDA | Moran Kevin Patrick | SVP, CFO, Treas | S - Sale | $19.24 | -2,130 | 99.3K | -2% | -$41.0K | |
| 2021-07-27 | 2021-07-26 | VNDA | Jones Aranthan II | Chief Corp. Affairs Off | S - Sale | $19.69 | -7,250 | 86.7K | -8% | -$142.8K |
Purchase Sale Sale after option exercise All abbreviations